3 ms·
Any single agent will usually need to prove itself as somewhat efficacious on its own. Almost certainly, safety (phase 1 trial) will be tried as a single agent
by epistasis 5y ago
Any single agent will usually need to prove itself as somewhat efficacious on its own. Almost certainly, safety (phase 1 trial) will be tried as a single agent before trying combination therapies.
However, some of our best chemotherapy regimes are combinations of many agents, such as FOLFOX and FOLFIRI in colon cancer. But to get there was a long process.
There is an idea of synthetic lethality, where a single gene getting shut off by a drug has no effect, but combining (the synthesis part) with a second gene getting shutoff causes cell death. This is an extreme case of epistasis (my gene name), but the challenge of doing trials with this is that the search space is quadratic or worse, rather than linear. And number of people enrolled in clinical trials is an extremely valuable resource.
Which is what leads to making sure that we start with single agent trials, to prove both safety and hopefully efficacy of these single agents. The combinations come later, because they are so complex and difficult in terms of finding something with efficacy and in terms of managing side effects and adverse events.
- jcims 5y agoWhat you're saying makes complete sense. I just struggle at times with decisions like these because because there are millions of people sick today where the disease has broken through Avastin's ability to constrain tumor size and this might be what's needed to put it over the edge. On the other hand, anti-angiogenics are frequently not even made available in a post surgery context, particularly if perforations are a concern, so having some kind of agent that can throttle tumor growth without impacting compromised tissue would be a benefit. I guess there are no good answers until we can do whole body simulations to test drugs and all of their corner cases en masse.